Why the study?
The influence of BMI on clinical outcomes in patients with AF remains controversial, particularly among Asian patients.
Does body mass index affect clinical outcomes in Asian patients with atrial fibrillation receiving oral anticoagulation?
Does body mass index affect clinical outcomes in Asian patients with atrial fibrillation receiving oral anticoagulation?
In Asian patients with atrial fibrillation on oral anticoagulation, higher BMI is independently associated with lower risks of ischemic stroke, major bleeding, and all-cause mortality, demonstrating an obesity paradox.
Answers are grounded in this paper and cite their sources.
Should not yet alter risk stratification by BMI in Asian AF on OAC; leaves open obesity paradox confirmation in prospective trials.
BACKGROUND AND PURPOSE: The influence of body mass index (BMI) on clinical outcomes in patients with atrial fibrillation remains controversial, especially among Asians. We aimed to evaluate the association between BMI and clinical outcomes in Asian patients with atrial fibrillation receiving oral anticoagulants. METHODS: Using the Korean National Health Insurance database between January 2015 and December 2017, we identified oral anticoagulant new users among patients with nonvalvular atrial fibrillation who had BMI information. We analyzed ischemic stroke, intracranial hemorrhage, hospitalization for gastrointestinal bleeding, major bleeding, all-cause death, and the composite clinical outcome according to BMI categories. RESULTS: increase) was significantly associated with lower risks of ischemic stroke (hazard ratio [HR], 0.891 [95% CI, 0.801-0.992]), hospitalization for gastrointestinal bleeding (HR, 0.785 [95% CI, 0.658-0.937]), major bleeding (HR, 0.794 [95% CI, 0.686-0.919]), all-cause death (HR, 0.658 [95% CI, 0.605-0.716]), and the composite clinical outcome (HR, 0.751 [95% CI, 0.706-0.799]), except for intracranial hemorrhage (HR, 0.815 [95% CI, 0.627-1.061]). The underweight group was associated with an increased risk of composite clinical outcome (HR, 1.398 [95% CI, 1.170-1.671]), mainly driven by an increased risk of all-cause death. The effects of non-vitamin K antagonist oral anticoagulant versus warfarin on clinical outcomes were similar across BMI groups. CONCLUSIONS: Higher BMI was independently associated with a lower risk of ischemic stroke, major bleeding, and better survival. Underweight patients had a higher risk of all-cause death and composite clinical outcome. The optimal BMI for patients with atrial fibrillation should be defined and managed according to an integrated care pathway.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: